Gilead Sciences, Inc (GIS) – cijena dionice i vijesti

Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19. It also develops medicines in therapeutic areas such as oncology and inflammation and cell therapy. In 1987, Michael L. Riordan founded the company under the name Oligogen. The original name was a reference to oligonucleotides, small strands of DNA used to target genetic sequences. Gilead held its initial public offering in 1992, and successfully developed drugs including Tamiflu and Vistide that decade. In the 2000s, Gilead began evolving from a biotechnology company into a large pharmaceutical company, through acquisitions and investments, acquiring several subsidiaries. Gilead is a member of the Nasdaq-100 and the S&P 100. The company has faced criticism over its business practices, including extremely high pricing of drugs such as Sovaldi and Truvada in the United States relative to production cost and cost in the developing world. Wikipedia

Gilead Sciences, Inc – informacije

Glavni izvršni direktorDaniel O'Day

Zaposlenici17 tis.

Osnovano22. lip 1987.

SjedišteFoster City, Kalifornija, Sjedinjene Američke Države

Sektor-

Web-lokacijagilead.com

Sve vrijednosti su u valuti USD	ruj 2025.	pro 2025.	ožu 2026.	lip 2026.
Prihod	7,77 mlr.	7,92 mlr.	6,96 mlr.	7,80 mlr.
Trošak prodane robe	1,57 mlr.	1,62 mlr.	1,44 mlr.	1,58 mlr.
Trošak prihoda	1,57 mlr.	1,62 mlr.	1,44 mlr.	1,58 mlr.
Izdaci za istraživanje i razvoj	1,33 mlr.	1,57 mlr.	1,36 mlr.	1,69 mlr.
Ukupni izdaci za istraživanje i razvoj	-	-	-	-
Izdaci za prodaju, opći i administrativni izdaci	1,35 mlr.	1,78 mlr.	1,43 mlr.	1,91 mlr.
Poslovni rashod	2,69 mlr.	3,34 mlr.	2,78 mlr.	3,60 mlr.
Ukupni poslovni rashodi	4,26 mlr.	4,96 mlr.	4,23 mlr.	5,18 mlr.
Poslovni prihod	3,51 mlr.	2,96 mlr.	2,73 mlr.	2,63 mlr.
Ostali neposlovni prihod	−23,00 mil.	51,00 mil.	−8,00 mil.	-
Zarada prije poreza uključujući neuobičajene stavke	3,64 mlr.	2,08 mlr.	2,58 mlr.	−10,25 mlr.
Zarada prije poreza isključujući neuobičajene stavke	3,34 mlr.	2,80 mlr.	2,59 mlr.	2,42 mlr.
Izdaci za porez na dohodak	589,00 mil.	−105,00 mil.	559,00 mil.	242,00 mil.
Efektivna porezna stopa	16,18 %	−5,05 %	21,67 %	−2,36 %
Ostali poslovni rashodi	-	-	-	-
Neto dohodak	3,05 mlr.	2,18 mlr.	2,02 mlr.	−10,50 mlr.
Neto profitna marža	39,28 %	27,55 %	29,04 %	−134,51 %
Zarada po dionici	2,47	1,86	2,03	−6,75
Prihod od kamata i ulaganja	88,00 mil.	95,00 mil.	95,00 mil.	45,00 mil.
Izdaci za kamate	−256,00 mil.	−255,00 mil.	−240,00 mil.	−247,00 mil.
Neto izdaci za kamate	−168,00 mil.	−160,00 mil.	−145,00 mil.	−202,00 mil.
Troškovi amortizacije i otpisa	-	-	-	-
Dobit prije kamata, poreza i amortizacije	4,20 mlr.	3,65 mlr.	3,42 mlr.	3,33 mlr.
Dobit ili gubitak od prodaje imovine	-	-	-	-

Pitajte bilo što